OLD Category: skin disease
April 17, 2024 / JID Innov
Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model
Previous work done by our laboratory described the use of an immunocompetent spontaneous melanoma-prone mouse model, TGS (TG-3/SKH-1), to evaluate treatment outcomes using inhibitors of glutamatergic signaling and immune checkpoint…
February 2, 2024 / Sci Immunol
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma
Adoptive cell therapy (ACT) using ex vivo-expanded tumor-infiltrating lymphocytes (TILs) can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a fraction of patients. Using longitudinal samples…
June 16, 2023 / Clin Cancer Res
Activin A-mediated polarization of cancer-associated fibroblasts and macrophages confers resistance to checkpoint immunotherapy in skin cancer
Purpose: Cemiplimab is approved for the treatment of locally advanced basal cell carcinomas (BCCs), however with mitigated results. We sought to interrogate the cellular and molecular transcriptional reprogramming underlying BCC…
May 30, 2023 / Cells
The Vicious Cycle of Melanoma-Microglia Crosstalk: Inter-Melanoma Variations in the Brain-Metastasis-Promoting IL-6/JAK/STAT3 Signaling Pathway
Previous studies from our lab demonstrated that the crosstalk between brain-metastasizing melanoma cells and microglia, the macrophage-like cells of the central nervous system, fuels progression to metastasis. In the present…
March 8, 2023 / Eur Urol
Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer
Background: Most renal cell carcinomas (RCCs) are localized and managed by active surveillance, surgery, or minimally invasive techniques. Stereotactic ablative radiation (SAbR) may provide an innovative non-invasive alternative although prospective…
March 3, 2023 / J Invest Dermatol
MULTIPLATFORM ANALYSIS OF INTRATUMORAL PTEN HETEROGENEITY IN MELANOMA
Loss of protein expression of the tumor suppressor PTEN is associated with increased cancer aggressiveness, decreased tumor immune infiltration, and resistance to immune and targeted therapies in melanoma. We assessed…
February 27, 2023 / Transl Med Commun
A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors
Background: This window of opportunity trial evaluated the safety of intratumoral Copaxone® and profiled immune markers in biopsies before and after treatment. Methods: Patients with percutaneously accessible malignancies scheduled for…
November 11, 2022 / Sci Immunol
Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells
September 16, 2022 / J Invest Dermatol
Disease Association of Anti‒Carboxyethyl Lysine Autoantibodies in Hidradenitis Suppurativa
June 2, 2022 / Cancer Discov